Martin Stockler

Grappling with oncology, clinical research, quality of life, prognostication, communication, education, rabbitohs, wallabies, cricket, and other enigmas

[South Sydney Rabbitohs 🐰 @SSFCRABBITOHS]

Strong first 40, let's keep it going 💪

#MGMotor

[Aarthi S Jayraj @JayrajAarthi]

An amazing opportunity to learn how to do pragmatic trials in low resource settings by none other than @AsimaMukhopadh1
Don't miss it!
@IJGConline @IJGCfellows @nissiemburu @Lawalqdus @MaryCEiken @Bhandoria @Suvidyasingh20 @KapoorShagun10 @HsuMd @AnaTatianaPala1 @FlorenciaNoll

[Jia (Jenny) Liu MD PhD @JiaJennyLiu]

2011 PhD student → 2025 drug development oncologist.

A long road, a lot of growth, and so many people to thank along the way.

Grateful to be promoted to Conjoint Associate Professor at @UNSW.

Excited for the next stage of global collaboration in early phase trials 🧬🧫🔬👩🏻‍⚕️

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: Meta-Analysis

https://t.co/U8xUGsAl2e

Meta-analysis of over 10,000 patients from 13 randomized trials found that the survival benefit of androgen deprivation therapy (ADT) combined with radiotherapy is highly dependent on both treatment duration and patient risk profile, with diminishing returns beyond roughly 9–12 months and increasing non–cancer-related mortality with prolonged therapy. Optimal duration varied by disease severity—shorter or no ADT for lower-risk intermediate disease, longer courses for higher-risk groups—highlighting that extended therapy is not universally beneficial.

Because longer ADT improves cancer-specific outcomes but also increases other-cause mortality, the study emphasizes tailoring duration based on individual risk, comorbidities, life expectancy, and patient preference rather than applying uniform treatment lengths. #ProstateCancer

@NicholasZaorsky
@yilun_sun
@StatMatt9
@DrHowardSandler
@drjefstathiou
@Soum_Roy_RadOnc
@DrPaulNguyen
@jeshoag
@PBarataMD
@angela_jia_
@MSteinbergMD
@AmarUKishan
@DrSpratticus

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists

[Martin Stockler @MartinStockler]

Wonderful to see, @Nickymitchell, looking forward to seeing the fruits of your efforts in in March and September! @oncodocsydney @ChrisKarapetis @JiaJennyLiu @pankajpanda86 @yysoon01 #acordism

[Nicky Lawrence @nickymitchell]

Very inspiring AoNZ concept development workshop today! Bring on #ACORD26 @MartinStockler

[Jia (Jenny) Liu MD PhD @JiaJennyLiu]

Just published a paper co-authored with early-phase trial patients.

It took far longer than it should have… a sign of how undervalued patient experience still is in oncology.

Cancer drug development must be human-centred, not just molecule-centred.

🔗: https://t.co/gp94RUBGsB

[Nicky Lawrence @nickymitchell]

Very inspiring AoNZ concept development workshop today! Bring on #ACORD26 @MartinStockler

[Patrick Forde @FordePatrick]

Great to see Prof. @perth_meso_dr present results of our international phase 3 #mesothelioma trial #DREAM3R today at #ESMO25 a really enjoyable academic trial collaboration between @TOGAANZ @PrECOGonc

[Shilpa Gupta @shilpaonc]

@batraatulonc @neerajaiims @montypal @MartinStockler @winsoncheung Congratulations on your oral talk on low dose pembro in breast ca. It's such important work! Was great seeing you again!

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

ENZARAD (ANZUP 1303) Presented at #ESMO25
ADT with radiation therapy with or without enzalutamide for high risk, clinically localised #ProstateCancer

https://t.co/aUAzAUfzkb

Adding enzalutamide to ADT 💊and radiation provided limited overall survival benefit in high-risk localized or locally advanced prostate cancer, with greater metastasis-free survival seen in patients with positive pelvic nodes or planned pelvic radiation☢️

@DrPaulNguyen
@ChrisSweens1
@MartinStockler
@DocJarad
@DavePryorRO
@PaulKRadiation
@Prof_IanD

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@nataliagandur
@bavilima

[Linda Mileshkin @LindaMileshkin]

Great way to start Day 2 of #IGCS2025 with a Run for Hope to raise funds for Gynae cancer!

[Linda Mileshkin @LindaMileshkin]

The discussant @ShannonWestin intrigued by the OS curves in the ECHO trial which although not significant currently may improve with time. Also pointing out that PFS was excellent in both arms.

[Linda Mileshkin @LindaMileshkin]

Well done on a great presentation of the @anzgog ECHO trial by Sandy Hayes at #IGCS2025 this am. Why were the results different from the Challenge trial? Reassuring for women having chemo for ovarian cancer to know that if they don’t feeling like walking every day it is ok!

[Prof Lennart Nacke, PhD @acagamic]

Rejected within 24 hours.

That’s how my academic journey really started.

My writing has never been the same since.
Here’s what I learned from 300+ submissions:

Too many papers get rejected instantly.

[Aparna Raj Parikh @aparna1024]

Honored to be named Program Director for GI Medical Oncology @MGHCancerCenter , focused on CRC, Anal & NET. Grateful to collaborate with incredible colleagues like @KlempnerSam leading UGI and Harsh Singh joining us for HBP. excited to build on innovation & equity in cancer care.

[Dr Sujana Priya MD;DNB; FRCR @sujanapriya]

~Look who all we met @BalcoMedical annual conference @aparna1024 @ajumathew_ @MartinStockler @arunighose @SirohiBhawna One of the best events in recent times in scale & content
#aighospitals #aigoncology

[bhawna sirohi @SirohiBhawna]

What an amazing feat the @BalcoMedical team pulled off .. meeting attended by >1000 with almost 200 from india, 12 globally from australia, NZ, UK, USA, Lebanon, Switzerland, singapore. key tracks were mini Accord research workshop, communication skills with role play to train Oncologist into communicating prognosis and having end of life conversations with the patients and caregivers, radiotherapy contouring workshop, surgery workshop for head neck cancers. choosing wisely themed GIGU and lung Cancer, cancer prevention workshop, which mainly discussed HPV vaccine implementation, district level cancer prevention programmes. This was attended by state level, health officers and on ground level. Mitanin/Asha workers from Chhattisgarh. meeting was attended by 65 oncology students all over the country. Top 10 posters will be published in @ecancer . Looking forward to September 2026, .. have an amazing line up of @oncology_bg , ian prof Tannock, @prof_gina_brown @ajumathew_ @lateuwen and more ! Thank you to @TataMemorial @ACTREC_TMC @CancerGridIndia @ASCO @myESMO @csoncol @Shrikhande_SV @JavleMilind @MDAndersonNews @VanitaNoronha @nitaSnair

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

@SirohiBhawna @MartinStockler @pankajpanda86 @BalcoMedical I will. Sorry I haven’t been able to make it last 2 years but next year, I plan to! Have a nice workshop.

[bhawna sirohi @SirohiBhawna]

So grateful to our health minister honourable @ShyamBihariBjp for inaugurating the @BalcoMedical annual conclave and inspiring us to serve the nation ! Spoke so eloquently on the importance of health for all especially women as part of स्वस्थ नारी सशक्त परिवार स्वास्थ्य प्रदेश स्वास्थ्य भारत विकसित भारत अभियान!! Thank you 🙏🏽 @MartinStockler @drkiwicj @drshonanag @pankajpanda86 @aparna1024 @SusannahStanwa1 @y2k2011

[Pankaj Kumar Panda @pankajpanda86]

In a single frame with two The New England Journal of Medicine @NEJM legends Prof @MartinStockler and Prof @docdcruz

#BALCOCancerConclave @ecancer

@SirohiBhawna @BalcoMedical